Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Elsewhere, Stoboclo and Osenvelt have received regulatory endorsements in the European Union and Korea. Amgen’s Prolia and Xgeva were initially approved in 2010 to treat osteoporosis and ...

A closing highlight of the programme is the joint symposium for all European Amgen Scholars in Cambridge, UK. In addition to conducting hands-on research, you will attend workshops and events offering ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...